骨质疏松及其治疗作为关节置换与脊柱融合植入物固定失败的决定因素:国际骨质疏松基金会科学顾问委员会骨折工作组立场声明
该专家立场声明将关节置换和脊柱融合并发症统一为「植入物固定失败」终点,综合机制与临床证据,提出围手术期骨健康优化的循证建议。低骨密度与植入物固定失败相关;双膦酸盐可保持假体周围骨密度,抗骨吸收和合成代谢治疗影响脊柱融合参数,其中合成代谢药物证据最一致。
要点
- 低骨密度与关节置换和脊柱融合的植入物固定失败相关。
- 双膦酸盐可保持关节置换术后假体周围骨密度,注册分析提示植入物生存改善。
- 脊柱融合中合成代谢药物对融合质量和早期愈合的证据最一致。
核心结论
- 以统一构建体层面视角看待关节置换和脊柱融合并发症,可将骨质疏松与重建耐久性联系起来。
- 系统性围手术期骨健康优化可能改善构建体寿命,但仍需更多以结局为导向的确定性试验。
研究设计与样本
- 遵循结构化文献检索制定的立场声明,证据以叙述性方式综合。
- 将植入物固定失败定义为涵盖假体周围骨折、松动、下沉、骨不连和交界性失败的构建体层面结局。
- 推荐意见按强度(强或条件性)和证据确定性(高、中、低)分类。
主要发现
- 低骨密度与关节置换和脊柱融合的植入物固定失败相关。
- 关节置换中,随机试验显示双膦酸盐可保持假体周围骨密度,注册分析提示植入物生存改善。
- 脊柱融合中,抗骨吸收和合成代谢治疗影响固定相关参数,合成代谢药物对融合质量和早期愈合的证据最一致。
- 许多文献依赖影像学或生物力学终点,而非确定性结局。
关键数值与推荐
- 推荐意见按强度(强或条件性)和证据确定性(高、中、低)分类。
- 植入物固定失败定义为涵盖假体周围骨折、松动、下沉、骨不连和交界性失败的构建体层面结局。
临床怎么用
- 围手术期应系统评估和优化骨健康,以可能改善构建体寿命。
- 骨科医生与骨质疏松专家需更紧密整合,以推进围手术期骨健康管理。
局限性
- 许多文献依赖影像学或生物力学终点,而非确定性结局。
- 仍需更多以结局为导向的确定性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This expert position statement reframes arthroplasty and spinal fusion complications under the unified endpoint of implant fixation failure, defined as loss of mechanical integrity of the bone-implant unit over time. It synthesizes mechanistic and clinical evidence and provides evidence-informed recommendations for peri-operative bone health optimization. BACKGROUND: Osteoporosis is traditionally conceptualized as causing fragility fractures. However, compromised bone quality also affects the integrity of bone-implant constructs, influencing whether implants maintain fixation, interfaces remain stable, and fusion constructs consolidate. OBJECTIVE: To synthesize mechanistic, translational, and clinical evidence on how osteoporosis and osteoporosis pharmacotherapies influence implant fixation failure across arthroplasty and spinal fusion, and to provide evidence-informed clinical recommendations for peri-operative bone health assessment and optimization within a unified construct-level framework. METHODS: A position statement was developed following a structured literature search. Evidence was synthesized narratively by defining implant fixation failure as a construct-level outcome encompassing periprosthetic fracture, loosening, subsidence, pseudarthrosis, and junctional failure. Recommendations were categorized by strength (strong or conditional) and certainty of evidence (high, moderate, or low). RESULTS: Low bone mineral density (BMD) is associated with implant fixation failure across arthroplasty and spinal fusion. In arthroplasty, randomized trials demonstrate preservation of periprosthetic BMD with bisphosphonates, while registry analyses suggest improved implant survival. In spinal fusion, antiresorptive and anabolic therapies influence fixation-related parameters, with anabolic agents showing the most consistent evidence for enhanced fusion mass and earlier union. Much of the literature relies on radiographic or biomechanical endpoints rather than definitive outcomes. CONCLUSIONS: Viewing arthroplasty and spinal fusion complications through a shared construct-level perspective provides a coherent link between osteoporosis and reconstructive durability. Systematic peri-operative bone health optimization may improve construct longevity, although more definitive outcome-driven trials are needed. Closer integration between orthopedic surgeons and osteoporosis specialists will be central to advancing peri-operative bone health care.
引用
- Chandran M, Anastasilakis AD, Blank RD, et al. Osteoporosis and osteoporosis therapies as determinants of implant fixation failure in arthroplasty and spinal fusion constructs: a position statement from the Fracture Working Group of the Council of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2026. PMID: 42313180. doi:10.1007/s00198-026-08086-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。